Nluc Reporter Cell Line - JJN-3

The JJN-3 cell line is a human multiple myeloma cell line derived from the peripheral blood of a patient with plasma cell leukemia. As an important model for studying hematological malignancies, JJN-3 cells exhibit typical characteristics of myeloma cells, including robust proliferation in suspension culture and expression of typical surface markers such as CD38 and CD138. These cells are particularly known for their resistance to conventional chemotherapeutic drugs, making them a valuable tool for studying drug resistance mechanisms in multiple myeloma. Researchers utilize JJN-3 cells to explore disease pathogenesis, tumor microenvironment interactions, and the efficacy of novel therapeutic approaches, including proteasome inhibitors and immunomodulatory drugs.

The Nluc reporter cell line - JJN-3 is a genetically engineered variant of the JJN-3 cell line that incorporates the NanoLuc luciferase (Nluc) reporter gene, enabling highly sensitive bioluminescent detection for a variety of research applications. Because Nluc offers higher brightness and stability than traditional luciferases, this modification allows researchers to monitor cellular processes such as cell proliferation, apoptosis, and drug response in real-time with extremely high signal-to-noise ratios. In drug discovery, this cell line facilitates high-throughput screening of anti-myeloma compounds by quantifying luminescence changes associated with cell viability or specific pathway activation. Furthermore, it serves as a powerful in vivo imaging tool in xenograft models for non-invasively tracking tumor burden and treatment response over time.